CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.81B, above the global median of $1.15B
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.81BUSDvs all stocks (USD)
Revenue (TTM)
32.08MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.18xvs all stocks
52-Week Change
135.99%vs all stocks
Market Capitalization
1.81BUSDvs all stocks (USD)
Enterprise Value
1.47BUSDvs all stocks (USD)
Forward P/E
-9.40xvs Biotechnology peers
Price to Sales (TTM)
56.40xvs Biotechnology peers
Price to Book (MRQ)
4.58xvs Biotechnology peers
Enterprise to Revenue
45.80xvs Biotechnology peers
Enterprise to EBITDA
-8.01xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-857.57%vs Biotechnology peers
Return on Assets (TTM)
-27.24%vs Biotechnology peers
Return on Equity (TTM)
-45.58%vs Biotechnology peers
Revenue (TTM)
32.08MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.5300USDUpdated Jul 19, 2026Quarterly Revenue Growth
-96.10%vs Biotechnology peers
Gross Profit (TTM)
32.08MUSDvs all stocks (USD)
EBITDA (TTM)
-183.52MUSDvs all stocks (USD)
Net Income (TTM)
-169.77MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-96.07%vs Biotechnology peers
Operating Cash Flow (TTM)
-146.82MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-88.69MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
184.42MUSDFY2025 · Dec 31, 2025Operating Income
-20.59MUSDvs all stocks (USD)
Pre-tax Income
-6.88MUSDFY2025 · Dec 31, 2025Net Income
-6.88MUSDFY2025 · Dec 31, 2025EBIT
-20.59MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-18.82MUSDFY2025 · Dec 31, 2025Research & Development
137.92MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
67.09MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-6.88MUSDFY2025 · Dec 31, 2025Operating Cash Flow
25.13MUSDFY2025 · Dec 31, 2025Free Cash Flow
24.46MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
84.94MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-6.88MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.77MUSDFY2025 · Dec 31, 2025Stock-based Compensation
32.24MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.41MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-4.27MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-130.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-670.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-322.72MUSDFY2025 · Dec 31, 2025Sale of Investments
136.58MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-186.81MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
87.78MUSDFY2025 · Dec 31, 2025Shares Outstanding
62.24MSharesUpdated Jul 19, 2026Float Shares
46.77MSharesUpdated Jul 19, 2026Shares Short
13.91MSharesUpdated Jul 19, 2026Short Ratio
14.73daysvs all stocks
Short % of Shares Outstanding
23.23%vs all stocks
% Held by Insiders
3.82%vs all stocks
% Held by Institutions
120.21%vs all stocks
Total Cash (MRQ)
343.54MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.52USDUpdated Jul 19, 2026Total Debt (MRQ)
3.42MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0087xvs Biotechnology peers
Current Ratio (MRQ)
8.99xvs Biotechnology peers
Book Value per Share (MRQ)
6.34USDUpdated Jul 19, 2026Total Assets
418.43MUSDvs all stocks (USD)
Total Current Assets
305.70MUSDFY2025 · Dec 31, 2025Total Liabilities
65.98MUSDFY2025 · Dec 31, 2025Total Non-current Assets
112.73MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
8.10MUSDFY2025 · Dec 31, 2025Total Current Liabilities
57.88MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
84.22MUSDFY2025 · Dec 31, 2025Other Short-term Investments
200.45MUSDFY2025 · Dec 31, 2025Accounts Receivable
5.94MUSDFY2025 · Dec 31, 2025Accounts Payable
4.94MUSDFY2025 · Dec 31, 2025Short-term Debt
3.01MUSDFY2025 · Dec 31, 2025Deferred Revenue
11.90MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.06MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
1.14MUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-497.71MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
352.46MUSDvs all stocks (USD)
52-Week Low
12.25USDUpdated Jul 19, 202652-Week High
40.22USDUpdated Jul 19, 202652-Week Change
135.99%vs all stocks
Beta
1.18xvs all stocks
50-Day MA
30.80USDUpdated Jul 19, 2026200-Day MA
31.56USDUpdated Jul 19, 2026Avg 10-Day Volume
642.34KSharesUpdated Jul 19, 2026Avg 30-Day Volume
897.72KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.86USDUpdated Jul 19, 2026Other Income / Expense
-51.00KUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.81B, above the global median of $1.15BNotable
Market cap (USD): 1,809,282,015Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
PolyPeptide Group AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Bausch Health Companies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Olymvax Biopharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sarepta Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ani Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bicara Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
D&D Pharmatech Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
BeBetter Med Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Idorsia Ltd
Tier 1ProductionApproval-Gated PipelineRuleRisk
OneSource Specialty Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow